Cortone (cortisone acetate) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 8 Diseases   2 Trials   2 Trials   133 News 


«12
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients (ENDOExpo) -  Feb 7, 2020 - Abstract #ENDO2020ENDO_3425;    
    The appearance of fatigue, the typical symptom of PAI, could be multifactorial in these pts due also to the direct effect of TKIs treatment. Thus, in these cases is very difficult to recognize the cause of fatigue and to decide the appropriate treatment (cortisone acetate replacement therapy vs TKIs dose reduction).
  • ||||||||||  Cortone (cortisone acetate) / Merck (MSD)
    Journal:  Hyperthyroidism and hypopituitarism: two incompatible diagnoses? (Pubmed Central) -  Jan 31, 2020   
    Therapy with cortisone acetate, L-thyroxine and testosterone was started, resulting in prolonged normalization of the clinical picture...In a few months span H disappeared and central hypothyroidism manifested again, so that the patient is still taking replacement therapy. This case illustrates how H and hypopituitarism are not mutually exclusive diagnoses and how, even if rarely, central hypothyroidism and H could alternate in the clinical history of the same patient.
  • ||||||||||  Caprelsa (vandetanib) / Sanofi, Cortone (cortisone acetate) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  PRIMARY ADRENAL INSUFFICIENCY DURING LENVATINIB OR VANDETANIB AND IMPROVEMENT OF FATIGUE AFTER CORTISONE ACETATE THERAPY. (Pubmed Central) -  Dec 21, 2019   
    Patients with PAI received cortisone acetate (CA) replacement therapy, with a significant and prompt improvement in the degree of fatigue, as assessed by the CTCAE Version 4.03, thus supporting the major impact of the impaired adrenal function in the genesis of this adverse event. We show for the first time that the occurrence of PAI may be a frequent cause of fatigue during Lenvatinib and Vandetanib treatment, and we thus recommend testing adrenal function for a prompt start of replacement therapy in order to avoid discontinuation of treatment or dose reduction, as well as potentially severe PAI complications.
  • ||||||||||  hydrocortisone / generics
    Journal:  Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. (Pubmed Central) -  Jun 30, 2019   
    No significant differences between high and low doses of both conventional GCs and DR-HC were observed. DR-HC is associated with an improvement of metabolic parameters and cardiovascular risk compared to conventional GCs, which are associated with a worsening of these parameters, regardless of the dose used.
  • ||||||||||  fosmanogepix (APX001) / Amplyx Pharma, APX001 / 3SBio, Apexigen
    APX001 protects immunosuppressed mice from scedosporiosis (Arena 2) -  Apr 5, 2019 - Abstract #ECCMID2019ECCMID_4064;    
    APX001 protected immunosuppressed mice from scedosporiosis due to S. apiospermum. Continued investigation of APX001 as a novel antifungal agent against scedosporiosis is warranted.
  • ||||||||||  cyclophosphamide intravenous / Generic mfg.
    Novel Cloudbreak bifunctional molecule protects against Acinetobacter  pneumonia () -  Apr 5, 2019 - Abstract #ECCMID2019ECCMID_2146;    
    Cpd-A has potent activity against AB mouse infection possibly by a dual killing mechanism and by reducing LPS-induced vascular leak. Continued investigation of Cpd-A as a novel treatment for MDR-GNB is warranted.
  • ||||||||||  hydrocortisone / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date, IO biomarker:  Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) (clinicaltrials.gov) -  Jun 27, 2017   
    P4,  N=89, Completed, 
    Trial completion date: Sep 2018 --> Sep 2019 | Recruiting --> Suspended | Trial primary completion date: Jan 2018 --> Oct 2018 Recruiting --> Completed | N=50 --> 89 | Trial primary completion date: Sep 2015 --> Jun 2016
  • ||||||||||  Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer, Cortone (cortisone acetate) / Merck (MSD)
    Enrollment open:  CAH: Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia (clinicaltrials.gov) -  Dec 21, 2016   
    P2,  N=20, Recruiting, 
    Recruiting --> Completed | N=50 --> 89 | Trial primary completion date: Sep 2015 --> Jun 2016 Active, not recruiting --> Recruiting
  • ||||||||||  Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer, Cortone (cortisone acetate) / Merck (MSD)
    Enrollment closed:  CAH: Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia (clinicaltrials.gov) -  Dec 4, 2015   
    P2,  N=20, Active, not recruiting, 
    Trial primary completion date: Dec 2015 --> Sep 2017 Recruiting --> Active, not recruiting
  • ||||||||||  Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer, Cortone (cortisone acetate) / Merck (MSD)
    Trial primary completion date:  CAH: Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia (clinicaltrials.gov) -  Apr 14, 2015   
    P2,  N=20, Recruiting, 
    Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Jan 2015 --> Jan 2017